Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)

July 8, 2024 12:33 PM EDT Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $66.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login